镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展  

Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases

作　　者：桂继琮[1] 刘兴党[1] 

机构地区：[1]复旦大学附属华山医院核医学科,上海200040

出　　处：《国际放射医学核医学杂志》2015年第3期268-272,共5页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：近年来，全世界前列腺癌的发病率和病死率不断增长，各种治疗方法的研究也进展迅速。镭-223发射的重α粒子（具有＜100μm的超短波）靶向作用于骨转移部位和周围新骨生长区域。镭-223氯化物在药物临床试验中以稳定的安全性显著降低了患者的病死率，成为近来被寄予厚望的转移性去势抵抗性前列腺癌（CRPC）治疗领域的“主角”。2013年美国食品药品管理局已批准镭-223氯化物用于治疗有症状的骨转移、未发现内脏转移的CRPC患者。未来其联合治疗方案将会是研究的重点。Prostate carcinoma rates and mortalities are increasing worldwide. The therapeutic landscape of castration-resistant prostate carcinoma （CRPC） has changed rapidly. Radium-223 chloride, which is a radiopharmaceutical agent, targets bone metastasis by emitting high-energy alpha-particles with extremely short range （〈100 μm ） . This chemical is effective in reducing mortality without increasing toxicity. Thus, this agent has the potential to become a new alternative for treating patients with CRPC. The Food and Drug Administration approved radium-223 dichloride for treating patients with CRPC, symptomatic bone metastases, and unknown visceral metastatic disease in 2013. Therefore, combination and sequencing strategies will be future research directions.

关 键 词：镭 氯化物 前列腺肿瘤 肿瘤转移 

分 类 号：R737.25[医药卫生—肿瘤] R730.55[医药卫生—临床医学]